ARDX Ardelyx, Inc.

NASDAQ
$3.18

Ardelyx, Inc. (ARDX) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is $0.03 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.7% since its last earnings release on November 3, 2026.

Ardelyx Beat Consensus Estimates, Reaffirms
Tuesday, November 3, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs $0.03
Rev est $142.06M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.07

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ardelyx, Inc.

Ardelyx Inc is a clinical stage biopharmaceutical company. The Company engages in the discovery, development & commercialization of non-systemic, molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal & metabolic diseases.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.